Introduction\nPrimary plasma cell leukemia (pPCL) is a rare and aggressive plasma cell proliferation with a very poor prognosis. The prevalence of poor-risk genetic lesions is higher compared with newly diagnosed multiple myeloma. pPCL requires urgent control of clinical manifestations to prevent early...
Plasma cell leukemia (PCL) is a rare aggressive hematological malignancy that originates either as primary disease (pPCL) or as secondary leukemic transformation (sPCL) of multiple myeloma. It represents less than 5% of malignant plasma cell diseases and so far a few studies based on several ...
摘要: (2015). Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for the treatment of secondary plasma cell leukemia. Leukemia & Lymphoma: Vol. 56, No. 1, pp. 232-235. doi: 10.3109/10428194.2014.893304DOI: 10.3109/10428194.2014.893304 被引量: 3 ...
The Cancer and Leukemia Group B (CALGB) undertook the present study in 1974 based on this concept and the pilot findings. During the period when this study was being planned, two methods for administration of ara-C were in common use: intravenous (i.v.) infusion continuously for several ...
Leukemia (2016) 30, 526–535; doi:10.1038/leu.2015.223 INTRODUCTION Multiple myeloma (MM) is a malignancy of antibody-secreting plasma cells.1 Globally, over 80 000 new cases of MM are reported each year, representing ~ 1% of all new cancer cases and 10% of all hematologic malignancies.2...
10. Kaiser MF, Hall A, Walker K, et al: Depth of response and minimal residual disease status in ultra high-risk multiple myeloma and plasma cell leukemia treated with daratumumab, bortezomib, lenalidomide, cyclophosphamide and dexamethasone: Results of the UK OPTIMUM/MUKnine trial.2021 ASCO Annu...
Convalescent plasma improves overall survival in patients with B-cell lymphoid malignancy and COVID-19: a longitudinal cohort and propensity score analysis. Leukemia. 2022;36(4):1025-1034. doi:10.1038/s41375-022-01511-6PubMedGoogle ScholarCrossref 35. Lanza F, Monaco F, Ciceri F...
S-palmitoylation is essential for cancer development via regulating protein stability, function and subcellular location, yet the roles S-palmitoylation plays in diffuse large B-cell lymphoma (DLBCL) progression remain enigmatic. In this study, we uncove
Pomalidomide in patients with multiple myeloma: potential impact on the reconstitution of a functional T-cell immunity Jiaxin Shen Francesca Senes Claudio Fozza Immunologic Research(2024) Leukemia (Leukemia)ISSN1476-5551(online)ISSN0887-6924(print)...
In total, 12 MM and plasma cell leukemia cell lines were analyzed, and EC50 values ranged from 4 to 589 pg/ml with a mean of 180 pg/ml (Supplementary Table S1). Using MM.1R cells and purified T cells, activity of BI 836909-mediated lysis was observed at effector to target (E:T) ...